Allogene Therapeutics

Q3 FY2026 EarningsQ3 FY26 results for ALLO.US missed consensus estimates on both the top and bottom lines. Collaboration revenue was $0 vs. $2.22K expected, primarily due to the prior termination of the Overland Therapeutics license. R&D spending surged to $41.9M (+35% YoY) as the company reactivated manufacturing and advanced the ALPHA3 pivotal trial, leading to a GAAP EPS of -$0.15 vs. the -$0.147 expected. Despite the wider loss, a Q2 public offering bolstered the cash position to $388.9M, providing a runway into Q1 2029.